Medical+Health Clúster A.C.

Children

BNT162b2 Vaccine Effectiveness against Omicron in Children 5 to 11 Years of Age

Abstract BACKGROUND Limited evidence is available on the real-world effectiveness of the BNT162b2 vaccine against coronavirus disease 2019 (Covid-19) and specifically against infection with the omicron variant among children 5 to 11 years of age. METHODS Using data from the largest health care organization in Israel, we identified a cohort […]

Read More

Unexplained Hepatitis Reported in Nearly 200 Children Worldwide

Nearly 200 cases of unexplained hepatitis have been reported in children globally, according to the European Centre for Disease Prevention and Control (ECDC). As of April 20, 111 cases have been reported in the United Kingdom, and as of April 27, 55 cases have been reported in 12 countries in the European Union: Austria, […]

Read More

Coronavirus (COVID-19) Update: FDA Approves First COVID-19 Treatment for Young Children

Today, the U.S. Food and Drug Administration expanded the approval of the COVID-19 treatment Veklury (remdesivir) to include pediatric patients 28 days of age and older weighing at least 3 kilograms (about 7 pounds) with positive results of direct SARS-CoV-2 viral testing, who are: Hospitalized, or Not hospitalized and have […]

Read More

CDC: Omicron Hospitalization Doubled in Unvaxxed Children

Unvaccinated children ages 5 to 11 were more than twice as likely to be hospitalized for COVID-19 during the Omicron wave, and nearly a third of hospitalized kids overall had no underlying medical conditions while about a fifth required intensive care unit (ICU) admission, researchers found. From Dec. 19, 2021 […]

Read More

Masks Protected Children From COVID Last Fall: CDC Study

School mask mandates helped to protect children and teachers from the coronavirus last fall, according to a new study released by the CDC. Public school districts in Arkansas with mask requirements had 23% lower rates of the coronavirus among students and staff than districts without mandates from August to October 2021 as […]

Read More

Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5–17 Years — VISION Network, 10 States, April 2021–January 2022

Summary What is already known about this topic? Two doses of Pfizer-BioNTech vaccine provided protection against COVID-19 in persons aged 12–17 years during Delta predominance, but data during Omicron predominance and among children aged 5–11 years are lacking. What is added by this report? Two doses protect against COVID-19–associated emergency […]

Read More

Hospitalizations of Children and Adolescents with Laboratory-Confirmed COVID-19 — COVID-NET, 14 States, July 2021–January 2022

What is already known about this topic? COVID-19 can cause severe illness in children and adolescents. What is added by this report? Coinciding with increased circulation of the Omicron variant, COVID-19–associated hospitalization rates among children and adolescents aged 0–17 years increased rapidly in late December 2021, especially among children aged […]

Read More

Even More Safety and Effectiveness Data for COVID-19 Vaccines for Children

The FDA authorized the Pfizer vaccine for children ages 5–11 in October 2021, on the basis of studies showing a robust immune response, fewer cases of COVID, and minimal side effects in several thousand children. Since that time, millions of children have been vaccinated. The latter—minimal side effects—speaks to the […]

Read More
Translate »